Ajmal Aseem

Graduated from the University of Kerala with B.Sc. Botany and Biotechnology. Attained Post-Graduation in Biotechnology from the Kerala University of Fisheries and Ocean Science (KUFOS) with the third rank. Conducted various seminars and attended major Science conferences. Done 6 months of internship in ICMR – National Institute of Nutrition, Hyderabad. 5 years of tutoring experience.
Oncology News Regulatory Approval

FDA Approves Lilly’s Inluriyo (imlunestrant) for Advanced ER+, HER2- Breast Cancer with ESR1 Mutation

Eli Lilly and Company

The U.S. Food and Drug Administration (FDA) has officially approved Eli Lilly and Company’s Inluriyo (imlunestrant), a new oral therapy for adult patients with advanced or metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer that has an ESR1 mutation. The approval is based on the pivotal Phase 3 EMBER-3 trial, which demonstrated that Inluriyo significantly reduced the risk of disease progression or death by 38% in this patient population, offering a new and convenient treatment option for a challenging form of breast cancer.

Clinical Trials Autoimmune Diseases Healthcare & Pharmaceuticals News

Roche Highlights New OCREVUS® Data Demonstrating Benefit in Diverse MS Populations and Presents Promising Long-Term Fenebrutinib Results at ECTRIMS 2025

Roche

Roche is set to present a wealth of new data at the 41st ECTRIMS Congress, highlighting the expanding benefits of its flagship multiple sclerosis therapy, OCREVUS® (ocrelizumab). New findings demonstrate a significant reduction in disability progression for adults with advanced primary progressive MS (PPMS) and reinforce its safety for pregnant women and their infants. The presentation will also include the first comparative data for OCREVUS in pediatric MS. Alongside these updates, Roche will showcase promising two-year results for its investigational oral BTK inhibitor, fenebrutinib, which showed near-complete suppression of disease activity in patients with relapsing MS ahead of pivotal Phase III readouts.

Business Healthcare & Pharmaceuticals News

Pfizer Acquires Metsera in $4.9 Billion Deal, Bolsters Obesity Drug Portfolio

pfizer news

Pfizer has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera in a deal valued at an initial $4.9 billion, with the potential for an additional $2.4 billion in milestone payments. The acquisition is a strategic move to re-enter the lucrative weight-loss drug market by adding Metsera’s next-generation obesity and cardiometabolic disease treatments, including promising oral and injectable therapies, to Pfizer’s pipeline.

Healthcare & Pharmaceuticals News Vaccines

Ebola Vaccination Campaign Launched in Democratic Republic of Congo

World Health Organization

Health authorities in the Democratic Republic of the Congo (DRC), with the support of the World Health Organization (WHO) and other partners, have launched an Ebola vaccination campaign in the Bulape health zone of Kasai Province. This vital initiative aims to curtail the spread of the deadly virus following the declaration of an outbreak in the region earlier this month. The first recipients of the Ervebo Ebola vaccine include frontline health workers and individuals who have been in contact with infected patients.

Regulatory Approval Healthcare & Pharmaceuticals News

U.S. FDA Approves Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system), a Groundbreaking Bladder-Sparing Treatment for a High-Risk Form of Bladder Cancer

JohnsonAndJohnson

U.S. Food and Drug Administration (FDA) has officially approved INLEXZO™ (gemcitabine intravesical system), a novel drug-delivery system from Johnson & Johnson set to revolutionize care for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This first-of-its-kind therapy offers a significant bladder-sparing alternative for a high-risk patient group often facing complete bladder removal. Clinical trials showed an 82% complete response rate, marking a major advancement in bladder cancer treatment.

Clinical Trials Healthcare & Pharmaceuticals News Weight-loss Drugs

Wegovy® Shows Superior Cardiovascular Protection Over Tirzepatide in Real-World Study

novo nordisk

The landmark STEER study provides the first head-to-head real-world comparison of the cardiovascular benefits of Wegovy® and tirzepatide. In a study of over 21,000 adults with obesity and established cardiovascular disease, Wegovy® (semaglutide 2.4 mg) demonstrated a significantly greater reduction in the risk of heart attack, stroke, and death compared to tirzepatide.

Regulatory Approval Healthcare & Pharmaceuticals News Vaccines

FDA Approves Pfizer-BioNTech COVID-19 Vaccine for High-Risk Adults and Seniors

pfizer news

Pfizer and BioNTech’s updated COMIRNATY vaccine, targeting the LP.8.1 COVID-19 sublineage, gained FDA approval for use in seniors and high-risk individuals aged 5 to 64. The vaccine promises enhanced immune defense against current variants and is set for immediate distribution across the U.S.